A Phase 1 interventional study of OXN PR tablet in Chronic Pain, sponsored by Mundipharma (China) Pharmaceutical Co. Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-07-17.
Sponsored by Mundipharma (China) Pharmaceutical Co. Ltd (part of Mundipharma) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Chronic Pain with a site in China — 14 open to participants now, 15 under way, 1 of them phase 3. Chronic Pain · China.
Among the 43 studies in Chronic Pain with a site in China, this one is the 29th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2014, is one of 8 in phase 1, and was the 5th registered.
3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.
Browse Chronic Pain studies →14 of the 43 studies in Chronic Pain with a site in China are open now. Recruiting first, the newest first:
Shanghai Mental Health Center · Sites in China
Ages 18–80
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
Beijing Tiantan Hospital · Sites in China
Ages 18–64
Xuanwu Hospital, Beijing · Sites in China
Ages 50–90
The Second Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 487 Chronic Pain studies recruiting now, 240 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 80 across the 34 interventional studies, 300 across the 9 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mundipharma (China) Pharmaceutical Co. Ltd, one of the names counted as Mundipharma. Under that name alone:
Mundipharma (China) Pharmaceutical Co. Ltd is the lead sponsor of 19 studies on the registry; 1 is open to participants now.
Mundipharma has 9 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
2 of the studies in Chronic Pain with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07323914Phase 3Xuanwu Hospital, BeijingClinical Analgesic Management in Dementia | 2027-01-01 |
| NCT06897007Beijing Tiantan HospitalChanges in Ciprofol Dosage in Patients With Insomnia Undergoing Intravenous Anesthesia | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies in Chronic Pain with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, randomized, single-dose, parallel group study. The objectives of this study are to assess pharmacokinetics of oxycodone and naloxone from oxycodone/naloxone (OXN) prolonged release (PR) tablet 5/2.5 mg (OXN 5/2.5) and 20/10 mg (OXN 20/10) in Chinese patients with moderate to severe chronic non-malignant pain.
It will be conducted to assess the pharmacokinetics of OXN 5/2.5 and OXN 20/10 tablets. Subjects will be allocated to a sequence of two strength group in accordance with a random allocation schedule (RAS) in a 1:1 ratio.
Subjects will attend a screening visit within 14 days of the first (OXN) dosing day (Day 1).
Eligible subjects will then check into the study unit on the day before OXN dosing (Day -2). Subjects will be administered their OXN dose the next 2 morning (Day 1), following an overnight fast.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The subjects were randomized to receive a single dose of OXN prolonged release tablet 5/2.5mg for one time.
Drug: OXN PR tablet
The subjects were randomized to receive a single dose of OXN prolonged release tablet 20/10 mg for one time.
Drug: OXN PR tablet
Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg
Also known as: Targin
AUC0-48hr of Noroxycodone Plasma Concentration.
AUC0-48hr of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg will be analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone and metabolites in Chinese patients.
AUC0-t of Noroxycodone Plasma Concentration
AUC0-t of Noroxycodone plasma concentration.Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg will be analyzed .(If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf \< 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis. )
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone and metabolites in Chinese patients.
AUC_%Extrap of Noroxycodone Plasma Concentration
AUC_%Extrap of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUCinf of Noroxycodone Plasma Concentration
AUCinf of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Cmax of Noroxycodone Plasma Concentration
Cmax of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Lambda_z of Noroxycodone Plasma Concentration
Lambda_z of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
T1/2 of Noroxycodone Plasma Concentration
T1/2 of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Tmax of Noroxycodone Plasma Concentration
Tmax of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC0-48hr of Noroxymorphone Plasma Concentration
AUC0-48hr of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC0-t of Noroxymorphone Plasma Concentration
AUC0-t of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC_%Extrap of Noroxymorphone Plasma Concentration
AUC_%Extrap of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUCinf of Noroxymorphone Plasma Concentration
AUCinf of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Cmax of Noroxymorphone Plasma Concentration
Cmax of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Lambda_z of Noroxymorphone Plasma Concentration
Lambda_z of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
T1/2 of Noroxymorphone Plasma Concentration
T1/2 of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Tmax of Noroxymorphone Plasma Concentration
Tmax of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC0-48hr of Oxycodone Plasma Concentration
AUC0-48hr of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC0-t of Oxycodone Plasma Concentration
AUC0-t of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC_%Extrap of Oxycodone Plasma Concentration
AUC_%Extrap of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUCinf of Oxycodone Plasma Concentration
AUCinf of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Cmax of Oxycodone Plasma Concentration
Cmax of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Lambda_z of Oxycodone Plasma Concentration
Lambda_z of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
T1/2 of Oxycodone Plasma Concentration
T1/2 of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Tmax of Oxycodone Plasma Concentration
Tmax of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC0-48hr of Oxymorphone Plasma Concentration
AUC0-48hr of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC0-t of Oxymorphone Plasma Concentration
AUC0-t of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC_%Extrap of Oxymorphone Plasma Concentration
AUC_%Extrap of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUCinf of Oxymorphone Plasma Concentration
AUCinf of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Cmax of Oxymorphone Plasma Concentration
Cmax of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Lambda_z of Oxymorphone Plasma Concentration
Lambda_z of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
T1/2 of Oxymorphone Plasma Concentration
T1/2 of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Tmax of Oxymorphone Plasma Concentration
Tmax of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC0-48hr of 6-B-Naloxol Plasma Concentration
AUC0-48hr of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC0-t of 6-B-Naloxol Plasma Concentration
AUC0-t of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC_%Extrap of 6-B-Naloxol Plasma Concentration
AUC_%Extrap of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUCinf of 6-B-Naloxol Plasma Concentration
AUCinf of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Cmax of 6-B-Naloxol Plasma Concentration
Cmax of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Lambda_z of 6-B-Naloxol Plasma Concentration
Lambda_z of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
T1/2 of 6-B-Naloxol Plasma Concentration
T1/2 of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Tmax of 6-B-Naloxol Plasma Concentration
Tmax of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC0-48hr of NLLG Plasma Concentration
AUC0-48hr of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC0-t of NLLG Plasma Concentration
AUC0-t of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC_%Extrap of NLLG Plasma Concentration
AUC_%Extrap of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUCinf of NLLG Plasma Concentration
AUCinf of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Cmax of NLLG Plasma Concentration
Cmax of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Lambda_z of NLLG Plasma Concentration
Lambda_z of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
T1/2 of NLLG Plasma Concentration
T1/2 of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Tmax of NLLG Plasma Concentration
Tmax of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC0-48hr of NLXG Plasma Concentration
AUC0-48hr of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC0-t of NLXG Plasma Concentration
AUC0-t of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC_%Extrap of NLXG Plasma Concentration
AUC_%Extrap of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUCinf of NLXG Plasma Concentration
AUCinf of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Cmax of NLXG Plasma Concentration
Cmax of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Lambda_z of NLXG Plasma Concentration
Lambda_z of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
T1/2 of NLXG Plasma Concentration
T1/2 of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Tmax of NLXG Plasma Concentration
Tmax of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC0-48hr of Naloxone Plasma Concentration
AUC0-48hr of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC0-t of Naloxone Plasma Concentration
AUC0-t of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUC_%Extrap of Naloxone Plasma Concentration
AUC_%Extrap of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
AUCinf of Naloxone Plasma Concentration
AUCinf of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Cmax of Naloxone Plasma Concentration
Cmax of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Lambda_z of Naloxone Plasma Concentration
Lambda_z of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
T1/2 of Naloxone Plasma Concentration
T1/2 of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Tmax of Naloxone Plasma Concentration
Tmax of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
| Milestone | OXN Prolonged Release Tablet 5/2.5 mg | OXN Prolonged Release Tablet 20/10 mg |
|---|---|---|
| Started | 13 | 17 |
| Completed | 13 | 17 |
| Not completed | 0 | 0 |
AUC0-48hr of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg will be analyzed.
| hr*ng/mL | OXN PR Tablet 5/2.5 mg | OXN PR Tablet 20/10 mg |
|---|---|---|
| AUC0-48hr of Noroxycodone Plasma Concentration. | 81.72 ± 39.82 | 325.51 ± 99.47 |
AUC0-t of Noroxycodone plasma concentration.Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg will be analyzed .(If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf \< 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis. )
| hr*ng/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC0-t of Noroxycodone Plasma Concentration | 81.25 ± 40.27 | 325.37 ± 99.76 |
AUC_%Extrap of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| (%) | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC_%Extrap of Noroxycodone Plasma Concentration | 2.99 ± 1.17 | 1.45 ± 0.67 |
AUCinf of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*ng/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUCinf of Noroxycodone Plasma Concentration | 83.74 ± 41.66 | 330.44 ± 102.51 |
Cmax of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| ng/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Cmax of Noroxycodone Plasma Concentration | 4.68 ± 1.53 | 20.69 ± 3.88 |
Lambda_z of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| 1/hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Lambda_z of Noroxycodone Plasma Concentration | 0.10 ± 0.02 | 0.10 ± 0.01 |
T1/2 of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| T1/2 of Noroxycodone Plasma Concentration | 7.42 ± 1.42 | 7.16 ± 1.02 |
Tmax of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Tmax of Noroxycodone Plasma Concentration | 4.50 (1.50 to 8.02) | 4.00 (2.50 to 5.02) |
AUC0-48hr of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*ng/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC0-48hr of Noroxymorphone Plasma Concentration | 14.10 ± 5.02 | 65.84 ± 25.50 |
AUC0-t of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*ng/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC0-t of Noroxymorphone Plasma Concentration | 12.92 ± 5.21 | 65.65 ± 25.78 |
AUC_%Extrap of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| (%) | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC_%Extrap of Noroxymorphone Plasma Concentration | 14.89 ± 11.61 | 4.25 ± 1.98 |
AUCinf of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*ng/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUCinf of Noroxymorphone Plasma Concentration | 15.76 ± 4.68 | 68.17 ± 26.22 |
Cmax of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| ng/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Cmax of Noroxymorphone Plasma Concentration | 0.75 ± 0.29 | 3.54 ± 1.64 |
Lambda_z of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| 1/hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Lambda_z of Noroxymorphone Plasma Concentration | 0.08 ± 0.02 | 0.08 ± 0.01 |
T1/2 of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| T1/2 of Noroxymorphone Plasma Concentration | 8.55 ± 1.53 | 9.08 ± 1.42 |
Tmax of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Tmax of Noroxymorphone Plasma Concentration | 7.00 (2.00 to 10.00) | 5.00 (2.50 to 7.00) |
AUC0-48hr of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*ng/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC0-48hr of Oxycodone Plasma Concentration | 89.48 ± 34.38 | 272.11 ± 48.51 |
AUC0-t of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*ng/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC0-t of Oxycodone Plasma Concentration | 88.45 ± 34.55 | 271.21 ± 48.79 |
AUC_%Extrap of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| (%) | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC_%Extrap of Oxycodone Plasma Concentration | 1.78 ± 1.15 | 0.57 ± 0.21 |
AUCinf of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*ng/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUCinf of Oxycodone Plasma Concentration | 89.85 ± 34.72 | 272.71 ± 48.77 |
Cmax of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| ng/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Cmax of Oxycodone Plasma Concentration | 6.69 ± 1.67 | 24.64 ± 6.30 |
Lambda_z of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| 1/hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Lambda_z of Oxycodone Plasma Concentration | 0.14 ± 0.04 | 0.14 ± 0.02 |
T1/2 of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| T1/2 of Oxycodone Plasma Concentration | 5.09 ± 0.96 | 5.03 ± 0.69 |
Tmax of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Tmax of Oxycodone Plasma Concentration | 3.75 (1.02 to 8.00) | 2.00 (0.50 to 5.00) |
AUC0-48hr of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*ng/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC0-48hr of Oxymorphone Plasma Concentration | 3.70 ± 1.33 | 3.59 ± 0.97 |
AUC0-t of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*ng/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC0-t of Oxymorphone Plasma Concentration | 0.14 ± 0.33 | 1.66 ± 1.21 |
AUC_%Extrap of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| (%) | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC_%Extrap of Oxymorphone Plasma Concentration | 82.85 ± 21.51 | 51.11 ± 26.70 |
AUCinf of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
No measurements were reported for this outcome.
Cmax of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| ng/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Cmax of Oxymorphone Plasma Concentration | 0.03 ± 0.06 | 0.30 ± 0.17 |
Lambda_z of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
No measurements were reported for this outcome.
T1/2 of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
No measurements were reported for this outcome.
Tmax of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Tmax of Oxymorphone Plasma Concentration | 0.75 (0.50 to 1.00) | 1.75 (0.50 to 5.00) |
AUC0-48hr of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*pg/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC0-48hr of 6-B-Naloxol Plasma Concentration | 1655.48 ± 667.02 | 5065.33 ± 3358.14 |
AUC0-t of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*pg/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC0-t of 6-B-Naloxol Plasma Concentration | 1373.11 ± 779.63 | 5049.62 ± 3374.52 |
AUC_%Extrap of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| (%) | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC_%Extrap of 6-B-Naloxol Plasma Concentration | 21.24 ± 15.98 | 33.37 ± 15.60 |
AUCinf of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*pg/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUCinf of 6-B-Naloxol Plasma Concentration | 1828.39 ± 878.66 | — |
Cmax of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| pg/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Cmax of 6-B-Naloxol Plasma Concentration | 85.18 ± 47.25 | 269.53 ± 189.50 |
Lambda_z of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| 1/hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Lambda_z of 6-B-Naloxol Plasma Concentration | 0.07 ± 0.02 | — |
T1/2 of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| T1/2 of 6-B-Naloxol Plasma Concentration | 9.78 ± 2.20 | — |
Tmax of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Tmax of 6-B-Naloxol Plasma Concentration | 6.50 (0.50 to 14.00) | 1.75 (0.50 to 12.00) |
AUC0-48hr of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*pg/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC0-48hr of NLLG Plasma Concentration | 57735.72 ± 24399.37 | 209514.4 ± 104345.5 |
AUC0-t of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*pg/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC0-t of NLLG Plasma Concentration | 57737.49 ± 24400.80 | 209514.4 ± 104345.5 |
AUC_%Extrap of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| (%) | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC_%Extrap of NLLG Plasma Concentration | 13.13 ± 14.09 | 20.07 ± 9.23 |
AUCinf of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*pg/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUCinf of NLLG Plasma Concentration | 62953.71 ± 26257.03 | — |
Cmax of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| pg/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Cmax of NLLG Plasma Concentration | 3442.63 ± 1800.17 | 11372.74 ± 5426.77 |
Lambda_z of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| 1/hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Lambda_z of NLLG Plasma Concentration | 0.07 ± 0.02 | — |
T1/2 of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| T1/2 of NLLG Plasma Concentration | 11.32 ± 4.26 | — |
Tmax of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Tmax of NLLG Plasma Concentration | 11.00 (0.50 to 14.00) | 1.50 (0.50 to 7.00) |
AUC0-48hr of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*pg/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC0-48hr of NLXG Plasma Concentration | 78725.81 ± 28285.24 | 320734.4 ± 113332.8 |
AUC0-t of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*pg/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC0-t of NLXG Plasma Concentration | 77976.24 ± 28477.82 | 320734.4 ± 113332.8 |
AUC_%Extrap of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| (%) | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC_%Extrap of NLXG Plasma Concentration | 1.56 ± 1.05 | 1.86 ± 1.39 |
AUCinf of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*pg/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUCinf of NLXG Plasma Concentration | 79025.78 ± 28389.19 | 326907.3 ± 115103.6 |
Cmax of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| pg/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Cmax of NLXG Plasma Concentration | 11488.62 ± 2493.48 | 45789.83 ± 10576.00 |
Lambda_z of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| 1/hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Lambda_z of NLXG Plasma Concentration | 0.14 ± 0.03 | 0.09 ± 0.03 |
T1/2 of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| T1/2 of NLXG Plasma Concentration | 5.28 ± 1.35 | 8.40 ± 2.43 |
Tmax of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Tmax of NLXG Plasma Concentration | 1.01 (0.50 to 8.00) | 1.25 (0.50 to 3.00) |
AUC0-48hr of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*pg/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC0-48hr of Naloxone Plasma Concentration | 281.91 ± 122.61 | 650.42 ± 222.44 |
AUC0-t of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr*pg/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC0-t of Naloxone Plasma Concentration | 136.17 ± 92.95 | 443.88 ± 252.95 |
AUC_%Extrap of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| (%) | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| AUC_%Extrap of Naloxone Plasma Concentration | 47.82 ± 20.95 | 44.94 ± 26.95 |
AUCinf of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
No measurements were reported for this outcome.
Cmax of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| pg/mL | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Cmax of Naloxone Plasma Concentration | 33.21 ± 24.62 | 45.10 ± 21.03 |
Lambda_z of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
No measurements were reported for this outcome.
T1/2 of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
No measurements were reported for this outcome.
Tmax of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.
| hr | OXN Prolonged Release Tablet 5/2.5mg | OXN Prolonged Release Tablet 20/10mg |
|---|---|---|
| Tmax of Naloxone Plasma Concentration | 8.00 (5.00 to 14.00) | 1.00 (0.50 to 8.00) |
Collected over Events will be recorded from the point at which the Informed Consent is signed until 7(+3) days after the subject leaves the study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OXN PR Tablet 5/2.5 mg | 0/13 (0%) | 1/13 (7.7%) | 9/13 (69.2%) |
| OXN PR Tablet 20/10 mg | 0/17 (0%) | 0/17 (0%) | 13/17 (76.5%) |
| Event | OXN PR Tablet 5/2.5 mg | OXN PR Tablet 20/10 mg |
|---|---|---|
| upper respiratory tract infectionInfections and infestations | 1/13 | 0/17 |
| Event | OXN PR Tablet 5/2.5 mg | OXN PR Tablet 20/10 mg |
|---|---|---|
| SleepinessNervous system disorders | 4/13 | 6/17 |
| dizzinessNervous system disorders | 2/13 | 5/17 |
| nauseaGastrointestinal disorders | 0/13 | 5/17 |
| vomitGastrointestinal disorders | 1/13 | 5/17 |
| headacheNervous system disorders | 3/13 | 1/17 |
| Difficult defecationGastrointestinal disorders | 3/13 | 3/17 |
| HypertriglyceridemiaMetabolism and nutrition disorders | 2/13 | 1/17 |
| dry pharynxRespiratory, thoracic and mediastinal disorders | 0/13 | 2/17 |
| abdominal distensionGastrointestinal disorders | 1/13 | 2/17 |
| upper respiratory tract infectionInfections and infestations | 1/13 | 1/17 |
| Age, Categorical(Participants) | OXN PR Tablet 5/2.5 mg | OXN PR Tablet 20/10 mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 13 | 17 | 30 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | OXN PR Tablet 5/2.5 mg | OXN PR Tablet 20/10 mg | Total |
|---|---|---|---|
| Female | 7 | 8 | 15 |
| Male | 6 | 9 | 15 |
| Race and Ethnicity Not Collected(Participants) | OXN PR Tablet 5/2.5 mg | OXN PR Tablet 20/10 mg | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | OXN PR Tablet 5/2.5 mg | OXN PR Tablet 20/10 mg | Total |
|---|---|---|---|
| China | 13 | 17 | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2014 to primary completion in Jun 2015, 12 months.
Results were first posted in Jul 2019, 4 years 1 month after primary completion.
Of 27 industry-sponsored phase 1 interventional studies under Chronic Pain, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 12 months is above that.
Counting every sponsor, half of 60 studies reached it within 12 months; a quarter within 6 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxycodone naloxone combination
Mundipharma (China) Pharmaceutical Co. Ltd →